AstraZeneca PLC and Eli Lilly & Co. are to discontinue Phase III trials of their oral beta-site amyloid precursor protein cleaving enzyme (BACE) inhibitor lanabecestat in Alzheimer's disease. The two trials, one in early Alzheimer's and the other in mild Alzheimer's dementia, were stopped for futility on the recommendation of an independent data monitoring committee, which said they were unlikely to meet their primary endpoints on completion.
The field of BACE inhibition in Alzheimer's is littered with casualties, most recently Johnson & Johnson's atebecestat, which was...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
